Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06356155 · ClinicalTrials.gov registry record · Phase 2

Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer

A Phase 2 study of Urothelial Carcinoma, sponsored by University of Michigan Rogel Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
32
Enrollment target
1
Study location

NCT06356155 is a Phase 2 study of Urothelial Carcinoma that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 32 participants, below the 239-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06356155, a Phase 2 study of Urothelial Carcinoma, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

This trial is a multi-site, single-arm, phase 2 trial of neoadjuvant combination of enfortumab vedotin and pembrolizumab in cisplatin-eligible patients with high-grade localized/locally advanced cT1-4 N0-1 M0 upper tract urothelial cancer who are deemed eligible for curative-intent surgery (radical nephroureterectomy or distal ureterectomy) followed by adjuvant pembrolizumab.

Conditions Studied

Urothelial Carcinoma

Interventions

  • DRUG Pembrolizumab
  • DRUG Enfortumab vedotin

Study Locations (1)

Michigan

  • University of Michigan Comprehensive Cancer Center - Ann Arbor

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2025-07-22
Est. Completion 2028-03
Phase Phase 2

Sponsor

University of Michigan Rogel Cancer Center

292 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06356155

The ClinicalTrials.gov registry entry for NCT06356155 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (87% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Urothelial Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT06356155 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT06356155 about?

NCT06356155 is a clinical study titled "Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer". This trial is a multi-site, single-arm, phase 2 trial of neoadjuvant combination of enfortumab vedotin and pembrolizumab in cisplatin-eligible patients with high-grade localized/locally advanced cT1-4 N0-1 M0 upper tract urothelial cancer who are deemed eligible for curative-intent surgery (radical ...

What is the current status of trial NCT06356155?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2025-07-22. Estimated completion is 2028-03.

What conditions does trial NCT06356155 study?

This clinical trial studies the following conditions: Urothelial Carcinoma.

What interventions are being tested in trial NCT06356155?

The interventions under investigation include: Pembrolizumab (DRUG), Enfortumab vedotin (DRUG).

Who is sponsoring clinical trial NCT06356155?

This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06356155 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Urothelial Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Urothelial Carcinoma

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.